deltatrials
Completed PHASE3 NCT00086190

Study of Antidepressants in Parkinson's Disease

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Conditions Depression Parkinson Disease
Interventions paroxetine placebo venlafaxine
Updated 7 times since 2017 Last updated: Jan 3, 2013 Started: Jun 30, 2005 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009

This PHASE3 trial investigates Depression and Parkinson Disease and is currently completed. National Institute of Neurological Disorders and Stroke (NINDS) leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jun 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Neurological Disorders and Stroke (NINDS)
  • University of Rochester
Data source: University of Rochester

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States, Baltimore, United States, Boston, United States, Charlottesville, United States, Gainesville, United States, Houston, United States, Lexington, United States, London, Canada, Memphis, United States, Miami, United States and 7 more location s